MXCT vs NTAP · rev $38.6M vs P/E 28, rev $6.57B
MaxCyte Inc (MXCT) versus NetApp Inc (NTAP) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
NetApp Inc (NTAP) is a software - infrastructure company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported NTAP revenue for 2025-04-25 was $6.57B. Net income was $1.19B. Revenue was up 4.9% from 2024-04-26 to 2025-04-25. NTAP currently screens at market cap $35.43B and trailing P/E 28.2.
MXCT currently screens at market cap $124.3M. NTAP currently screens at market cap $35.43B and trailing P/E 28.2.
Not investment advice. Open the MXCT and NTAP stock pages for the full models.
Not investment advice.